PROMOTOR POLYMORPHISM OF IL-4, IL-6, AND IL-10 GENES AMONG PATIENTS WITH BREAST CANCER
https://doi.org/10.15789/1563-0625-2009-1-21-28
Abstract
In spite of extreme controversies on possible role of cytokines as regulating factors in cancer pathology, their role during carcinogenesis is beyond doubts. Since regulation of cytokine gene expression is known to proceed, mainly, at the level of transcription, from promoter region, we have undertaken an analysis of genotypic frequencies in promoter regions of IL-4, IL-6 and IL-10 genes for a group of relatively healthy women and patients with breast cancer. Some specific features of allelic distribution have been found in groups of healthy women, among cohorts with hereditary predisposition, including the patients with breast cancer who had clustering of the disease in families (i.e., mother, grandmother, or sister been affected).
About the Authors
A. V. ShevchenkoRussian Federation
O. V. Golovanova
Russian Federation
M. Ju. Kolomejtchuk
Russian Federation
V. I. Konenkov
Russian Federation
E. Ju. Garbukov
Russian Federation
M. N. Stakheeva
Russian Federation
References
1. Бабышкина Н.Н., Стахеева М.Н., Слонимская Е.М., Чердынцева Н.В., Гарбуков Е.Ю. Иммунологические параметры и уровень продукции цитокинов у больных с пролиферативными заболеваниями и раком молочной железы//Цитокины и воспаление. -2006 -Т. 5, №1. -С. 37-43.
2. Литовкин К.В., Доменюк В.П., Бубнов В.В., Запорожан В.Н. Полиморфизм -174G/C в промоторе гена IL-6 у больных раком молочной железы и миомой матки: популяционный анализ на основе сравнения контрольной и опытных групп -http://www.exp-oncology.com.ua/ru/archives/33/650.html.
3. Родионов С.Ю., Черешнев В.А., Орлова Е.Г., Тараненко Л.А., Сибиряк С.В., Орлов О.А., Шур Н.Н., Крапивина О.А., Суховая Д.А. Содержание сывороточных цитокинов у онкологических больных при иммуно-и полихимиотерапии с применением альфа-фетопротеина человека//Цитокины и воспаление. -2007.-Т. 6, № 3. -С. 36-39.
4. Тугуз А.Р., Анисимова Н.Ю., Вершинина М.В. Соотношение основных цитокинов в крови онкологических больных и здоровых доноров//Иммунология. -2003. -Т. 3. -С. 184-186.
5. Чердынцева Н.В., Перельмутер В.М., Слонимская Е.М., Литвяков Н.В., Стахеева М.Н., Гарбуков Е.Ю., Завьялова М.В., Глущенко С.А., Малиновская Е.А., Дорошенко А.В., Красулина Н.А. Молекулярно-генетические факторы прогрессии как критерии прогноза у больных со злокачественными новообразованиями молочной железы//Российский Онкологический Портал. X Российский онкологический конгресс. -М., 2006.
6. Balasubramanian S.P., Azmy I.A.F., Higham S.E., Wilson A.G., Cross S.S., Cox A., Brown N., Reed M.W. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review//BMC Cancer. -2006. -Vol. 188, N 6. -http://www.biomedcentral.com/1471-2407/6/188 <http://www.biomedcentral.com/1471-2407/6/188>.
7. Bland J.M., Altman D.G. Education and debate. The odds ratio//BMJ. -2000. -Vol. 320. -P. 1468.
8. Brower V. Researchers Attempting To Define Role of Cytokines in Cancer Risk//Journal of the National Cancer Institute. -2005. -Vol. 97, N 16. -P. 1175-1177.
9. Cantagrel A., Navaux F., Loubet-Lessonlie P. IL-1beta, IL-1 receptor antagonist, IL-4, and IL-10 gene polymorphisms//Arthr Rheum. -1999.-Vol. 42, N 6. -P. 1093-1100.
10. Caruso C., Lio D., Cavallone L., Franceschi C. Aging, Longevity, Inflammation, and Cancer//Ann. N.Y. Acad. Sci. -2004. -Vol. 1028. -P. 1-13.
11. Choi E., Lee H.J., Yoo T., Chanock S.A. Common haplotype of interleukin-4 gene IL-4 is associated with severe respiratory syncytial virus disease in Korean children//The Journal of Infectious Diseases.-2002. -Vol. 186. -P. 1207-1211.
12. Conze D., Weiss L., Regen P.S., Bhushan A., Weaver D., Johnson P., Rincon M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells//Cancer Res. -2001. -Vol. 61. -P. 8851-8858.
13. DeMichele A., Martin A.M., Mick R., Gor P., Wray L., Klein-Cabral M., Athanasiadis G., Colligan T.,S tadtmauer E., Weber B. Interleukin-6 (IL-6) -174G/C gene polymorphism and outcome after high dose chemotherapy (HDC) and autologous peripheral stem cell transplant (PSCT) for high risk breast cancer//Proc. Am. Soc. Clin. Oncol. -2002. -Vol. 21. -P. 170.
14. DeMichele A., Martin A.-M., Mick R., Gor P., Wray L., Klein-Cabra M., Athanasiadis G., Colligan T.,Stadtmauer E., Weber B. Interleukin-6 -174G→C polymorphism is associated with improved outcome in high-risk breast cancer//Cancer Res. -2003. -Vol. 63, N 22. -P. 8051-8056.
15. DeMichele A.D., Martin A.-M., Weber B.L. IL-6 variants as modifiers of breast cancer outcome//Proc. Amer. Assoc. Cancer Res. -2004. -Vol. 45. -P. 1316-1317.
16. Fernandez-Real J.-M., Vendrell J., Richart C., Gutierrez C., Ricart W. Platelet count and Interleukin 6 Gene polymorphism in healthy subjects//BMC Medical Genetics. -2001. -Vol. 2(6). -<http://www.biomedcentral.com/1471-2350/2/6>.
17. Gоосh J.L., Lee A.V., Yee D. Interleukin-4 inhibits growth and induces apoptosis in human breast cancer cells//Cancer research.-1998. -Vol. 58. -P. 4199-4205.
18. Guzowski D., Chandrasekaran A., Gawel C., Palma J., Koenig J., Ping Wang X., Dosik M.,Kaplan M.,Chu C.C., Chavan S., Furie R.,Albesiano E., Chiorazzi N., Goodwin L. Analysis of Single Nucleotide Polymorphisms in the Promoter Region of Interleukin-10 by Denaturing HighPerformance Liquid Chromatography//Journal of Biomolecular Techniques. -2005. -Vol. 16. -P. 154-166.
19. Heneghan M.A., Johnson P.J., Clare M., Ho S., Harrison P.M., Donaldson P.T. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese//Int. J. Gastrointest Cancer. -2003. -Vol. 34, N 1. -P. 19-26.
20. Howell W.M., Rose-Zerilli M.J. Cytokine Gene Polymorphisms, Cancer Susceptibility, and Prognosis//National Blood J. Nutr. -2007. -Vol. 137. -P. 194-199.
21. Hsieh Y.Y., Chang C.C., Tsai C.H., Lin C.C.,Tsai F.J. Interleukin (IL)-12 receptor beta1 codon 378 G homozygote and allele, but not IL-1 (beta-511 promoter, 3953 exon 5, receptor antagonist), IL-2 14, IL-4-590 intron 3, IL-8 3'-UTR 2767, and IL-18 105, are associated with higher susceptibility to leiomyoma//Fertil Steril. -2007. -Vol. 87 (4), -P. 886-895.
22. Kleinrath T., Gassner C., Lackner P., Thurnher M., Ramoner R. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma//J. Clin. Oncol.-2007.-Vol. 25, N 7. -P. 845-851.
23. Kundu N., Beaty T.L., Jackson M.J., Fulton A.M. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer//J. Natl. Cancer Inst. -1996. -Vol. 88, N 8. -P. 536-541.
24. Langsenlehner U., Kriрl P., Renner W., Yazdani-Biuki B., Eder T., Kцppel H., Wascher T.C., Paulweber B., Samonigg H. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk//Breast Cancer Research and Treatment. -2005. -Vol. 90, N 2. -P. 113-115.
25. Mock C.C., Lanchbury J.S., Chan D.W., Lau C.S. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus//Arthritis Rheum. -1998. -Vol. 41. -P. 1090-1095.
26. Nagai S., Toi M. Interleukin-4 and breast cancer//Breast Cancer. -2000. -Vol. 7(3). -P. 181-186.
27. Nishimura R., Nagao K., Miyayama H.,Matsuda M., Baba K., Matsuoka Y.,Yamashita H.,Fukuda M.,Mizumoto T., Hamamoto R. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer//Oncology. -2000. -Vol. 59. -P. 166-173.
28. Purohit A., Newman P.S., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer//Breast Cancer Res. -2002. -Vol. 4. -P. 65-69.
29. Slattery M.L., Curtin K., Baumgartner R., Sweeney C., Byers T., Giuliano A.R., Baumgartner K.B., Wolff R.R. IL-6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States//Cancer Epidemiol Biomarkers Prev. -2007. -Vol. 16, N 4. -P. 747-755.
30. Smith K.C., Bateman A.C., Fussell H.M., Howell W.M. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis//European Journal of Immunogenetics. -2004. -Vol. 31, N 4. -P. 167-173.
31. Vairaktaris E., Yannopoulos A., Vassiliou S., Serefoglou Z., Vylliotis A., Nkenke E., Critselis E. ,Avgoustidis D., Yapijakis C., Neukam F.W., Patsouris E. Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans//Oral Surg Oral Med Oral Pathol Oral Radiol Endod. -2007. -Vol. 104, N 6. -P. 796-802.
32. Venetsanakos E., Beckman I., Bradley J., Skinner J.M. High incidence of interleukin-10 mRNA but not interleukin-2 mRNA detected in human breast tumours//Br. J. Cancer. -1997. -Vol. 75, N 12. -P. 1826-1830.
33. Yannopoulos A., Nikiteas N., Chatzit-heofylaktou A., Tsigris C. The (-590 C/T) polymorphism in the interleukin-4 gene is associated with increased risk for early stages of corolectal adenocarcinoma//In Vivo. -2007. -Vol. 21, N 6. -P. 1031-1035.
34. Yokoe T., Iino Y., Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report//Breast Cancer. -2000. -Vol. 7. -P. 187-190.
35. Zhang G.J., Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma//Anticancer Res. -1999. -Vol. 19. -P. 1427-1432.
Review
For citations:
Shevchenko A.V., Golovanova O.V., Kolomejtchuk M.J., Konenkov V.I., Garbukov E.J., Stakheeva M.N. PROMOTOR POLYMORPHISM OF IL-4, IL-6, AND IL-10 GENES AMONG PATIENTS WITH BREAST CANCER. Medical Immunology (Russia). 2009;11(1):21-28. (In Russ.) https://doi.org/10.15789/1563-0625-2009-1-21-28